Tenax Therapeutics (TENX) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Tenax Therapeutics has expanded its partnership with Orion Corporation, amending their agreement to now include worldwide rights to develop and sell levosimendan-based products, excluding treatments for neurological conditions. The revision also adjusts financial terms, decreasing the royalties tied to global sales, while increasing milestone payments for FDA and Japanese regulatory approvals, and altering the commercial milestone payments. Additionally, it lowers the cost per capsule for Tenax, enhancing the company’s position in the market for these products.
For further insights into TENX stock, check out TipRanks’ Stock Analysis page.